95 results on '"Miravitlles, Marc"'
Search Results
2. N-acetylcysteine Treatment in Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis/Pre-COPD: Distinct Meta-analyses
3. The Natural History of Severe Chronic Obstructive Pulmonary Disease: The SPOCCAT Study Protocol
4. Sex-Differences in Alpha-1 Antitrypsin Deficiency: Data From the EARCO Registry
5. Association between occupational exposure and chronic obstructive pulmonary disease and respiratory symptoms in the Spanish population
6. Inhaled Maintenance Therapy in the Follow-Up of COPD in Outpatient Respiratory Clinics. Factors Related to Inhaled Corticosteroid Use. EPOCONSUL 2021 Audit
7. Tobacco Patterns and Risk of Chronic Obstructive Pulmonary Disease: Results From a Cross-Sectional Study
8. Estimated Worldwide Prevalence of the PI*ZZ Alpha-1 Antitrypsin Genotype in Subjects With Chronic Obstructive Pulmonary Disease
9. Variations in Chronic Obstructive Pulmonary Disease Outpatient Care in Respiratory Clinics: Results From the 2021 EPOCONSUL Audit
10. Trends of COPD in Spain: Changes Between Cross Sectional Surveys 1997, 2007 and 2017
11. Effectiveness of Treatment With Dual Bronchodilation (LABA/LAMA) Compared With Combination Therapy (LABA/ICS) for Patients With COPD: A Population-Based Study
12. [Translated article] Spanish COPD Guideline (GesEPOC) Update: Comorbidities, Self-Management and Palliative Care
13. [Translated article] Spanish COPD Guidelines (GesEPOC 2021): Non-pharmacological Treatment Update
14. Actualización de la Guía Española de la EPOC (GesEPOC): comorbilidades, automanejo y cuidados paliativos
15. Actualización 2021 de la Guía Española de la EPOC (GesEPOC). Tratamiento no farmacológico
16. [Translated article] Spanish COPD Guidelines (GesEPOC) 2021 Update. Diagnosis and Treatment of COPD Exacerbation Syndrome
17. Actualización 2021 de la guía española de la EPOC (GesEPOC). Diagnóstico y tratamiento del síndrome de agudización de la EPOC
18. [Translated article] Spanish COPD guidelines (GesEPOC) 2021: Updated pharmacological treatment of stable COPD
19. Effectiveness and Safety of Inhaled Antibiotics in Patients With Chronic Obstructive Pulmonary Disease. A Multicentre Observational Study
20. Actualización 2021 de la Guía Española de la EPOC (GesEPOC). Tratamiento farmacológico de la EPOC estable
21. Knowledge of chronic obstructive pulmonary disease, presence of chronic respiratory symptoms and use of spirometry among the Spanish population: CONOCEPOC 2019 study
22. Conocimiento de la enfermedad pulmonar obstructiva crónica, presencia de síntomas respiratorios crónicos y uso de la espirometría en la población española: estudio CONOCEPOC 2019
23. miR-320c Regulates SERPINA1 Expression and Is Induced in Patients With Pulmonary Disease
24. miR-320c Regulates SERPINA1 Expression and Is Induced in Patients With Pulmonary Disease
25. HLA-DRB1 Alleles are Associated With COPD in a Latin American Admixed Population
26. HLA-DRB1 Alleles are Associated With COPD in a Latin American Admixed Population
27. Treatment Pathways Before and After Triple Therapy in COPD: A Population-based Study in Primary Care in Spain
28. Treatment Pathways Before and After Triple Therapy in COPD: A Population-based Study in Primary Care in Spain
29. Changes in Control Status of COPD Over Time and Their Consequences: A Prospective International Study
30. Changes in Control Status of COPD Over Time and Their Consequences: A Prospective International Study
31. Results of a Diagnostic Procedure Based on Multiplex Technology on Dried Blood Spots and Buccal Swabs for Subjects With Suspected Alpha1 Antitrypsin Deficiency
32. Prevalence and Determinants of COPD in Spain: EPISCAN II
33. Blood Eosinophil Counts and Their Variability and Risk of Exacerbations in COPD: A Population-Based Study
34. Prevalence and Determinants of COPD in Spain: EPISCAN II
35. Results of a Diagnostic Procedure Based on Multiplex Technology on Dried Blood Spots and Buccal Swabs for Subjects With Suspected Alpha1 Antitrypsin Deficiency
36. Blood Eosinophil Counts and Their Variability and Risk of Exacerbations in COPD: A Population-Based Study
37. Clinical characteristics and risk of exacerbations associated with different diagnostic criteria of asthma-COPD overlap
38. Características clínicas y riesgo de agudizaciones asociados con diferentes criterios diagnósticos del solapamiento asma-EPOC
39. Serum Levels of Alpha1-antitrypsin and Their Relationship With COPD in the General Spanish Population
40. Serum Levels of Alpha1-antitrypsin and Their Relationship With COPD in the General Spanish Population
41. Patients With Chronic Obstructive Pulmonary Disease Exacerbations: Recommendations for Diagnosis, Treatment and Care
42. Paciente exacerbador con enfermedad pulmonar obstructiva crónica: recomendaciones en procesos diagnósticos, terapéuticos y asistenciales
43. 10 Years After EPISCAN: A New Study on the Prevalence of COPD in Spain—A Summary of the EPISCAN II Protocol
44. Nuevo estudio sobre la prevalencia de la EPOC en España: resumen del protocolo EPISCAN II, 10 años después de EPISCAN
45. Recommendations on Non-Pharmacological Treatment in Chronic Obstructive Pulmonary Disease From the Spanish COPD Guidelines (GesEPOC 2017)
46. Characteristics of COPD Patients Managed in Respiratory Medicine Departments in Spain, According to GOLD Groups and GesEPOC Clinical Phenotypes
47. Recomendaciones sobre tratamiento no farmacológico en la enfermedad pulmonar obstructiva crónica de la Guía española de la EPOC (GesEPOC 2017)
48. Características de los pacientes con EPOC tratados en neumología en España según grupos GOLD y fenotipos clínicos GesEPOC
49. Medical Care According to Risk Level and Adaptation to Spanish COPD Guidelines (GesEPOC): The Epoconsul Study
50. Atención médica según el nivel de riesgo y su adecuación a las recomendaciones de la guía española de la enfermedad pulmonar obstructiva crónica (EPOC) (GesEPOC): Estudio EPOCONSUL
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.